Amalgamated Bank Beam Therapeutics Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,619 shares of BEAM stock, worth $75,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,619

Previous 2,619 -0.0%

Holding current value

$75,977

Previous $61,000 4.92%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$21.22 - $32.66 $3,098 - $4,768	146 Added 5.9%	2,619 $61,000
Q1 2024 Apr 23, 2024	SELL	$23.46 - $45.07 $172,313 - $331,039	-7,345 Reduced 74.81%	2,473 $82,000
Q4 2023 Feb 06, 2024	SELL	$17.69 - $30.76 $318 - $553	-18 Reduced 0.18%	9,818 $267,000
Q2 2023 Aug 11, 2023	BUY	$29.32 - $35.99 $26,036 - $31,959	888 Added 9.92%	9,836 $314,000
Q1 2023 May 02, 2023	SELL	$30.15 - $48.79 $46,521 - $75,282	-1,543 Reduced 14.71%	8,948 $274,000
Q4 2022 Feb 10, 2023	BUY	$36.73 - $51.6 $7,639 - $10,732	208 Added 2.02%	10,491 $410,000
Q3 2022 Nov 09, 2022	BUY	$39.79 - $70.31 $9,668 - $17,085	243 Added 2.42%	10,283 $490,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $49,597 - $103,579	1,661 Added 19.82%	10,040 $389,000
Q1 2022 Jun 30, 2022	SELL	$53.73 - $82.16 $33,581 - $51,350	-625 Reduced 6.94%	8,379 $480,000
Q4 2021 Feb 15, 2022	BUY	$68.02 - $99.06 $9,658 - $14,066	142 Added 1.6%	9,004 $718,000
Q3 2021 Oct 29, 2021	SELL	$84.37 - $133.6 $843 - $1,336	-10 Reduced 0.11%	8,862 $771,000
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $204,671 - $410,842	3,192 Added 56.2%	8,872 $1.14 Million
Q1 2021 May 13, 2021	SELL	$71.28 - $120.75 $37,350 - $63,273	-524 Reduced 8.45%	5,680 $455,000
Q4 2020 Feb 12, 2021	BUY	$22.24 - $95.63 $137,976 - $593,288	6,204 New	6,204 $506,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.04B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Beam Therapeutics Inc. Transaction History